Pfizer Inc (NYSE: PFE), Moderna Inc (NASDAQ: MRNA) and Johnson & Johnson (NYSE: JNJ) Booster Jabs For All Who Are 18+, Six Months After Receiving The Second Dose

Pfizer Inc (NYSE: PFE), Moderna Inc (NASDAQ: MRNA) and Johnson & Johnson (NYSE: JNJ) booster dose of the vaccine against coronavirus is administered.

Those above 18 can select which booster dose they want

Those over 18-years of age can select which of the three dosages they wish to be administered. Pfizer and Moderna booster shot is administered six months after receiving the second jab. Johnson & Johnson booster shot is administered two months after receiving the first and the only shot. Those who are 16 and 17-years are eligible only for the Pfizer booster.

Those with weak immune systems could get the fourth dose of Pfizer or Moderna booster shot

The Centers for Disease Control and Prevention (CDC) announced that those with a weak immune system qualify to receive the third dose of the Pfizer or Moderna vaccine 28-days after the second dose. And six-months after being administered with the third dose, the fourth dose can be administered. In addition, the CDC has given its consent to mix and match booster jabs for vaccine against coronavirus.

Against the backdrop of a steady jump in coronavirus cases in the U.S. and globally, the CDC has cautioned that being administered with any available vaccines is safer than being unvaccinated. The center has also advised that people opt for Pfizer or Moderna, the mRNA-powered vaccines.

Pfizer Inc’s oral COVID-19 antiviral treatment Paxlovid receives emergency approval in South Korea

Pfizer Inc’s Paxlovid, the oral antiviral COVID-19 treatment, has received approval from the Ministry of Food and Drug Safety in South Korea. The nation saw a surge in coronavirus cases, despite 92% of its 18 and above population being vaccinated. As a result, the drug will be used to treat coronavirus patients who are at a risk of developing complications. In addition, children and adults with mild symptoms who weigh over 40-kgs and suffer from mild to moderate symptoms could be prescribed oral antiviral treatment.

Pfizer Inc will declare financial results in February 2022

Pfizer Inc will declare its financial result for 4Q 2021 and the annual results in February 2022. The group will share its performance report on the same day.

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. While reading this article one must assume that we may be compensated for posting this content on our website.

Published by Christine Lawrence

Christine Lawrence is a financial analyst. She loves analyzing socioeconomic trends in the background of financial moves. She has overall seven years of experience in Auditing, Finance and Writing.

Recent Stories

SignUp Now For Our Featured Newsletter